Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Chief Development Officer | November 20, 2024 | November 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date November 20, 2024 · Filed November 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 297,005 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Sale · Disposed 4,941 · Balance 297,005 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy Wife | 151,373 |
Reported balance
After 2024-11-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-20 · Sale · Disposed 2,243 · Balance 151,373 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2: The shares are directly held by the Reporting Person's wife. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 77,592 |
Reported balance
Holding disclosure · report date 2024-11-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 77,592 F3: The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F2: The shares are directly held by the Reporting Person's wife.
F3: The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2018 Filed Jul 30, 2018 23:49 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 54,730 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001140361-18-034301 · doc1.xml · derivative · entry 4 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,730 Underlying: Common Stock · 54,730 shares Expires 2028-07-26 F6 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/48 of the shares subject thereto on each monthly anniversary of July 26, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 23:49 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-034301 · doc1.xml · nonDerivative · entry 2 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,045 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 3,000 shares acquired by the Reporting Person's spouse under the ESPP on February 28, 2018. F4 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 23:49 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-034301 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,555 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 1,644 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on February 28, 2018. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 00:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 16,440 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001140361-18-002460 · doc1.xml · derivative · entry 2 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,440 Underlying: Common Stock · 16,440 shares Expires 2028-01-16 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. F2 · ownership.nature: The option is directly held by the Reporting Person's wife. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 00:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 117,104 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001140361-18-002460 · doc1.xml · derivative · entry 1 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,104 Underlying: Common Stock · 117,104 shares Expires 2028-01-16 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| December 27, 2017 Filed Apr 13, 2018 20:50 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 300 | $6.62 | $1,986.66 |
DisclosureSEC source: 0001140361-18-018552 · doc1.xml · nonDerivative · entry 2 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,045 F3 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 21:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 26,512 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001140361-17-031445 · doc1.xml · derivative · entry 4 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,512 Underlying: Common Stock · 26,512 shares Expires 2027-08-09 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 2/3 of the shares subject thereto on December 31, 2018 and 1/3 of the shares subject thereto on June 1, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 09, 2017 Filed Apr 13, 2018 20:50 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-018552 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,345 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 568 shares acquired under the Issuer's Employee Stock Purchase Plan on August 31, 2017. F3 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
| August 07, 2017 Filed Aug 11, 2017 21:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 26,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-031445 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,641 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 18, 2017 Filed Apr 21, 2017 22:57 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,051 | $11.98 | $24,577.34 |
DisclosureSEC source: 0001140361-17-016463 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,129 F1 · price: This transaction was executed in multiple trades in prices ranging from $11.90 to $12.15, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 17,985 restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,000 | $13.48 | $13,482.30 |
DisclosureSEC source: 0001140361-17-011981 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · SVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,277 F1 · shares: Includes 364 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017. F2 · balance_after: Consists of 1,277 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017. F3 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
| January 19, 2017 Filed Jan 24, 2017 01:50 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 106,047 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001140361-17-002601 · doc1.xml · derivative · entry 4 Rosenbaum David P. · CIK 0001611311 · SVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,047 Underlying: Common Stock · 106,047 shares Expires 2027-01-19 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 19, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 19, 2017 Filed Jan 24, 2017 01:50 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 17,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002601 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · SVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,129 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 16, 2016 Filed Dec 21, 2016 01:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 900 | $14.48 | $13,035.33 |
DisclosureSEC source: 0001140361-16-090420 · doc1.xml · nonDerivative · entry 1 Rosenbaum David P. · CIK 0001611311 · SVP, Drug Development 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 636 F1 · ownership.nature: The shares are directly held by the Reporting Person's wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.